Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of high-risk B-cell malignancies, but it remains associated with high rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). While prolonged toxicities are also observed in a subset of patients, to date the factors associated with the duration of CRS and ICANS are unknown. Here, we provide the first characterization of factors associated with time to CRS/ICANS resolution in patients receiving the FDA-approved CD19 CAR T-cell product axicabtagene ciloleucel (axi-cel).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Aya Albittar, Jenna M Voutsinas, Andrew J. Portuguese, Jennifer J Huang, Emily C. Liang, Natalie Wuliji, Vicky Wu, Xinyi Fan, Alexandre V Hirayama, Erik L. Kimble, Lorenzo Lovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Tags: 227 Source Type: research